Elutia Inc. - ELUT STOCK NEWS

Elutia reported Q3 2024 financial results, highlighting the first commercial implant of EluPro, their FDA-cleared antibiotic-eluting biologic envelope. Overall net sales decreased 3.3% to $5.9 million, with SimpliDerm sales growing 19% to $3.1 million. BioEnvelope products sales declined 12% to $2.3 million. The company reported net income of $1.3 million, primarily due to a $12.7 million non-cash warrant revaluation gain. EluPro has been submitted to over 100 hospital VACs, with 36 accounts actively ordering. The company maintains a strong cash position of $25.7 million and is preparing for EluPro's full commercial launch in January 2025.

Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix products, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21, 2024. The company's leadership team, including Dr. Randy Mills (President and CEO), Matt Ferguson (CFO), and Dr. Michelle LeRoux Williams (Chief Scientific Officer), will be available for one-on-one meetings with institutional investors during the event. Interested institutional investors can arrange meetings through their Canaccord representatives.

Elutia (Nasdaq: ELUT), a drug-eluting biomatrix products company, has scheduled its third quarter 2024 financial results release for Thursday, November 14, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. Management will be available for discussion, and investors can access the call through U.S. (877-407-8029) or International (201-689-8029) numbers using Conference ID 13749386.

Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix products, has announced its participation in the LD Micro Main Event XVII Conference in Los Angeles. Dr. Randy Mills, President and CEO, will deliver a presentation on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). The company's management team will also be available for one-on-one meetings with institutional investors, who can schedule appointments through LD Micro representatives or by contacting IR@elutia.com.

Elutia Inc. (ELUT) announced positive preclinical data for EluPro, the first FDA-cleared antibiotic-eluting biologic envelope for implantable devices. Published in Frontiers in Drug Delivery, the study showed EluPro's effectiveness in clearing bacterial contamination associated with cardiovascular implantable electronic devices (CIEDs). In a rabbit model, EluPro demonstrated complete eradication of MRSA and other bacterial strains with minimal systemic antibiotic exposure.

EluPro received FDA clearance for use with CIEDs in June 2024 and has been approved for additional devices. The first patient implant was completed in September 2024. Elutia is preparing for EluPro's commercial launch in January 2025.

Elutia Inc. (Nasdaq: ELUT) is celebrating its first anniversary since rebranding on September 6, 2023. The company, which focuses on drug-eluting biomatrix products, has achieved significant milestones in its inaugural year:

• Secured FDA approval for EluPro™, the first Antibiotic-Eluting BioEnvelope
• Successfully completed an FDA inspection of their manufacturing facility
• Implanted the first EluPro envelope on September 5, 2024
• Grew proprietary product sales by 20%
• Increased shareholder value by over 170%

The company's leadership expressed gratitude to stakeholders, partners, and employees for their contributions to Elutia's remarkable growth and accomplishments.

Elutia Inc. (Nasdaq: ELUT) has announced the first patient implant of EluPro™, the world's first FDA-cleared antibiotic-eluting biologic envelope for cardiac pacemakers and neurostimulators. The procedure was performed by Dr. John Catanzaro at East Carolina University Health Medical Center. EluPro is designed to prevent post-operative complications in patients with implantable devices.

Cleared by the FDA in June 2024, EluPro targets the $600 million U.S. implantable electronic device protection market. Elutia aims to establish a presence in the $8 billion cardiac rhythm management market and adjacent $8 billion neurostimulation sectors. The full commercial launch of EluPro is scheduled for January 2025.

Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix products, has announced its participation in two upcoming investor conferences in New York. Dr. Randy Mills, President and CEO, and Matt Ferguson, CFO, will represent the company at these events:

1. H.C. Wainwright 26th Annual Global Investment Conference:
- Presentation available on-demand from September 9, 2024, 7:00 a.m. ET
- One-on-one meetings on September 11, 2024

2. Lake Street Capital Markets 8th Annual Best Ideas Growth Conference:
- One-on-one meetings on September 12, 2024

Institutional investors can arrange meetings with Elutia's management through their H.C. Wainwright and Lake Street representatives.

Elutia (Nasdaq: ELUT) announced its financial results for Q2 2024. Key highlights include FDA clearance for EluPro, the first antibiotic-eluting BioEnvelope for implantable electronic devices, and a successful FDA inspection of its manufacturing facility. The company has commenced EluPro's production and expanded its commercial team. Financially, net sales were steady at $6.3 million. CanGaroo and SimpliDerm sales rose by 19% and 7% respectively, while cardiovascular product sales dropped 38%. Gross margin improved to 45% from 43%. However, total operating expenses increased to $11.3 million, resulting in a higher net loss of $28.2 million, primarily due to a non-cash charge of $18.3 million related to warrant revaluation. Adjusted EBITDA showed an improved loss of $2.9 million. The cash balance stood at $18.2 million, not including $13.8 million from warrant exercises post-quarter.